Atty. Dkt. No. 034536/0827 Appln. No. 09/822,295

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-11. (Canceled)

- Claim 12. (Currently Amended) An isolated, enriched, or purified PTP04 polypeptide, wherein said polypeptide comprises:
 - (a) an amino acid sequence comprising at least 90% identity to the full length amino acid sequence set forth in SEQ ID NO: 2;
 - (b) an amino acid sequence comprising a sequence having at least 90% identity over the length of amino acid residues 49-294 of to the full length amino acid sequence of the sequence set forth in SEQ ID NO: 2, except that it lacks and lacking amino acid residues 1-48 [[49-294 or 295-807]] of SEQ ID NO: 2;
 - (c) an amino acid sequence comprising a sequence having at least 90% identity over the length of amino acid residues 49-294 of SEQ ID NO:2 to the amino acid sequence set forth in amino acid residues 1-48, 49 294, or 295-807 of SEQ ID NO: 2; or
 - (d) an amino acid sequence comprising a sequence having at least 90% identity over the length of amino acid residues 49-294 of SEQ ID NO:2 to the full length amino acid sequence set forth in SEQ ID NO: 2 except that it lacks and lacking amino acid residues 1-48 or amino acid residues 295-807 an N-terminal domain or a C-terminal domain.

wherein said polypeptide possesses an enzymatic activity of a tyrosine phosphatase.

Claims 13-22. (Canceled)

Atty. Dkt. No. 034536/0827 Appln. No. 09/822,295

- Claim 23. (Previously Presented) The polypeptide of claim 12, wherein said polypeptide comprises an amino acid sequence comprising at least 95% identity to the full length amino acid sequence set forth in SEQ ID NO: 2.
- Claim 24. (Previously Presented) The polypeptide of claim 12 wherein said polypeptide comprises the full length amino acid sequence set forth in SEQ ID NO: 2.
- Claim 25. (Currently Amended) The polypeptide of claim 12, wherein said polypeptide comprises a sequence having an amino acid sequence comprising at least 95% identity over the length of to the amino acid sequence set forth in amino acid residues [[1 48,]]49 294 [[or 295 807]] of SEQ ID NO: 2.
- Claim 26. (Currently Amended) The polypeptide of claim 12, wherein said polypeptide comprises the amino acid sequence set forth in amino acid residues [[1 48,]] 49 294 [[or 295 807]] of SEQ ID NO: 2.
- Claim 27. (Currently Amended) The polypeptide of claim 12 wherein said polypeptide comprises an amino acid a sequence comprising having at least 95% identity over the length of amino acid residues 49-294 of SEQ ID NO:2 to the full length amino acid sequence set forth in SEQ ID NO: 2 except it lacks and lacking amino acid residues 1-48 or 295-807 of SEQ ID NO: 2.
- Claim 28. (Currently Amended) The polypeptide of claim 12 wherein <u>said</u> polypeptide comprises the full length amino acid sequence set forth in SEQ ID NO: 2 except it lacks amino acid residues 1-48 or 295-807 of SEQ ID NO:2.
- Claim 29. (Currently Amended) The polypeptide of claim 12 wherein said polypeptide comprises an amino acid a sequence comprising having at least 95% identity over the length of amino acid residues 49-294 of SEQ ID NO:2 to the full length amino acid-sequence set forth in SEQ ID NO: 2 except it lacks and lacking an N-terminal domain or a C-terminal domain.

Atty. Dkt. No. 034536/0827 Appln. No. 09/822,295

- Claim 30. (Currently Amended) The polypeptide of claim 12 wherein said polypeptide comprises the full length amino acid sequence set forth in SEQ ID NO: 2 except it lacks an N-terminal domain or a C-terminal domain.
- Claim 31. (Previously Presented) An isolated, enriched or purified polypeptide comprising the polypeptide of claim 12 fused to non-PTP04 polypeptide.
- Claim 32. (Canceled)
- Claim 33. (Previously Presented) A pharmaceutical composition comprising the polypeptide of claim 12.
- Claim 34. (Currently Amended) The isolated, enriched or purified polypeptide of claim [[33]] 31, wherein said non-PTP04 polypeptide is hemagglutinin or GST.